Google
Trusted Resources: News & Events
Latest announcements and gatherings
SUSTAIN Clinical Trial Results Show Crizanlizumab Reduced Sickle Cell–Related Pain Crises
Results from the Phase 2 SUSTAIN clinical trial demonstrated that crizanlizumab (SEG101, Selexys Pharmaceuticals, Novartis), an anti-P-selectin antibody, reduced by 45.3% the median annual rate of sickle cell-related pain crises (SCPC), compared to placebo in patients with or without hydroxyurea therapy, a drug used to reduce the rate of painful attacks in sickle-cell disease (SCD). Crizanlizumab also significantly extended time to first and second SCPC, the researchers reported.
These results were recently presented at the ASH Annual Meeting and Exposition, and published in the New England Journal of Medicine.
+myBinderRelated Content
-
Piracetam for reducing the incidence of painful sickle cell disease crisesBACKGROUND: Sickle cell disease is one ...
-
FDA Awards UNC Researcher $2M Grant to Study Kidney Disease in Sickle Cell AnemiaThe U.S. Food and Drug Administration (F...
-
New Method of Creating Healthy Stem Cells Could Potentially Improve Treatment of Sickle Cell AnemiaResearchers at New York’s Weill Cornel...
-
Only 21% of Kids with ADHD and SCD Are Treated for Attention DeficitA study of children with sickle cell dis...
-
Johns Hopkins researchers offer new protocol to potentially cure sickle cell diseaseThere's new hope for patients who have b...
-
The intersection between asthma and acute chest syndrome in children with sickle-cell anaemiaAcute chest syndrome is a frequent cause...
-
SCDAA Masterclass Speaker Series: All Things Considered – SCD Treatment: A Personal ChoiceSCDAA's First Masterclass on the Cusp of...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Powered by
Support for this site is provided by
This platform is made possible through a partnership with the Sickle Cell Disease Association of America, Inc. (SCDAA) and its member organizations. SCDAA's mission is to advocate for people affected by sickle cell conditions and empower community-based organizations to maximize quality of life and raise public consciousness while advancing the search for a universal cure.